Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Analysts
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers […]
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers […]
